Pharvaris NV Form 4 insider transactions

Anna Nijdam, Principal Accounting Officer at Pharvaris N.V., reported a sale of 2,670 common shares on June 4, 2026.

Pharvaris N.V. director Viviane Monges has corrected previously reported beneficial ownership and disposed of shares.

Anna Nijdam, Principal Accounting Officer at Pharvaris N.V., engaged in transactions involving the acquisition and sale of common stock, including cashless exercise of stock options.

Pharvaris N.V. CFO David W. Nassif reported the sale of 10,000 common shares and corrected a previous understatement of beneficial ownership.

Director Elisabeth Bjork exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. CEO Berndt Modig filed an amendment to a previous Form 4 to correct an omission of indirect shareholdings.

Pharvaris N.V. CEO Berndt Modig sold 2,292 shares of common stock on May 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Pharvaris N.V. Director Robert Glassman exercised stock options and sold 10,000 shares of common stock.

Chief Technical Operations Officer Stefan Abele sold 8,748 shares of Pharvaris N.V. common stock at an average price of $29.8199.

Chief Commercial Officer Wim Souverijns sold 10,000 shares of Pharvaris N.V. common stock via a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Peng Lu reported the withholding of 226 shares of Pharvaris N.V. common stock to satisfy tax obligations related to RSU vesting.

Pharvaris N.V. Chief Medical Officer Lu Peng executed a Rule 10b5-1 trading plan, involving the exercise of stock options and sale of common stock.

Pharvaris N.V. director Johannes Schikan sold 32,900 shares of common stock via a pre-arranged 10b5-1 trading plan.

Chief Early Development Officer Anne Lesage exercised options and sold shares of Pharvaris N.V. under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Peng Lu exercised and sold 18,733 shares of Pharvaris common stock under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. Director Johannes Schikan sold 7,100 shares of common stock under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. executive Anne Lesage reports transactions involving stock options and common stock sales, executed under a Rule 10b5-1 trading plan.

Pharvaris N.V. Chief Medical Officer Lu Peng executed a 10b5-1 trading plan involving the acquisition and sale of company stock.

Chief Medical Officer Peng Lu reported the withholding of 226 shares of Pharvaris N.V. common stock to satisfy tax obligations.

Pharvaris N.V. director Berndt Modig reported the sale of 2,292 shares of common stock for $28.60 per share under a pre-arranged trading plan.

Anna Nijdam, Principal Accounting Officer at Pharvaris N.V., reported a transaction involving the sale of common stock to cover tax withholding obligations.

Pharvaris CEO Berndt Modig reported the sale of 23,333 shares of common stock on April 9, 2026, under a pre-arranged trading plan.

Anna Nijdam, Principal Accounting Officer at Pharvaris N.V., reported a transaction involving the sale of 1,167 common shares.

Anna Nijdam, Principal Accounting Officer at Pharvaris N.V., reported a disposition of 1,164 common shares on April 1, 2026, to cover tax withholding obligations.